The long-term effect of the combination of estramustine and cyclophosphamide to castration resistant prostate cancer: A case report

Michihisa Saegusa, Shingo Nishimura, Kohei Edamura, Kyouhei Kurose, Shin Ebara

Research output: Contribution to journalArticle

Abstract

A 66-year-old man was diagnosed as prostate cancer of T2aN1M0, GS4+5. After CAB, radical prostatectomy was performed, and hormonal therapy was continued after operation. However he gadually became nonrespondent. At the time PSA become 17.38 ng/ml, combined application of estramustine (EMP) and cyclophosphamide (CPA) was started. PSA decreased gradually, and became below 0.01 ng/ml 14 months later, there-fore both medicines were discontinued on the 24th month. Adverse effects were only slight bone-marrow suppression. After 41 months, PSA became 0.02 ng/ml, and bone abnormality by CT also improved. The longterm effect of EMP and CPA, to castration resistant prostate cancer patient was thus achieved.

Original languageEnglish
Pages (from-to)167-170
Number of pages4
JournalJapanese Journal of Clinical Urology
Volume66
Issue number2
Publication statusPublished - Feb 20 2012

Fingerprint

Estramustine
Castration
Cyclophosphamide
Prostatic Neoplasms
Prostatectomy
Bone Marrow
Bone and Bones
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

The long-term effect of the combination of estramustine and cyclophosphamide to castration resistant prostate cancer : A case report. / Saegusa, Michihisa; Nishimura, Shingo; Edamura, Kohei; Kurose, Kyouhei; Ebara, Shin.

In: Japanese Journal of Clinical Urology, Vol. 66, No. 2, 20.02.2012, p. 167-170.

Research output: Contribution to journalArticle

@article{aa50b64f435442e58d3de7e52ee64a29,
title = "The long-term effect of the combination of estramustine and cyclophosphamide to castration resistant prostate cancer: A case report",
abstract = "A 66-year-old man was diagnosed as prostate cancer of T2aN1M0, GS4+5. After CAB, radical prostatectomy was performed, and hormonal therapy was continued after operation. However he gadually became nonrespondent. At the time PSA become 17.38 ng/ml, combined application of estramustine (EMP) and cyclophosphamide (CPA) was started. PSA decreased gradually, and became below 0.01 ng/ml 14 months later, there-fore both medicines were discontinued on the 24th month. Adverse effects were only slight bone-marrow suppression. After 41 months, PSA became 0.02 ng/ml, and bone abnormality by CT also improved. The longterm effect of EMP and CPA, to castration resistant prostate cancer patient was thus achieved.",
author = "Michihisa Saegusa and Shingo Nishimura and Kohei Edamura and Kyouhei Kurose and Shin Ebara",
year = "2012",
month = "2",
day = "20",
language = "English",
volume = "66",
pages = "167--170",
journal = "Japanese Journal of Clinical Urology",
issn = "0385-2393",
publisher = "Igaku-Shoin Ltd",
number = "2",

}

TY - JOUR

T1 - The long-term effect of the combination of estramustine and cyclophosphamide to castration resistant prostate cancer

T2 - A case report

AU - Saegusa, Michihisa

AU - Nishimura, Shingo

AU - Edamura, Kohei

AU - Kurose, Kyouhei

AU - Ebara, Shin

PY - 2012/2/20

Y1 - 2012/2/20

N2 - A 66-year-old man was diagnosed as prostate cancer of T2aN1M0, GS4+5. After CAB, radical prostatectomy was performed, and hormonal therapy was continued after operation. However he gadually became nonrespondent. At the time PSA become 17.38 ng/ml, combined application of estramustine (EMP) and cyclophosphamide (CPA) was started. PSA decreased gradually, and became below 0.01 ng/ml 14 months later, there-fore both medicines were discontinued on the 24th month. Adverse effects were only slight bone-marrow suppression. After 41 months, PSA became 0.02 ng/ml, and bone abnormality by CT also improved. The longterm effect of EMP and CPA, to castration resistant prostate cancer patient was thus achieved.

AB - A 66-year-old man was diagnosed as prostate cancer of T2aN1M0, GS4+5. After CAB, radical prostatectomy was performed, and hormonal therapy was continued after operation. However he gadually became nonrespondent. At the time PSA become 17.38 ng/ml, combined application of estramustine (EMP) and cyclophosphamide (CPA) was started. PSA decreased gradually, and became below 0.01 ng/ml 14 months later, there-fore both medicines were discontinued on the 24th month. Adverse effects were only slight bone-marrow suppression. After 41 months, PSA became 0.02 ng/ml, and bone abnormality by CT also improved. The longterm effect of EMP and CPA, to castration resistant prostate cancer patient was thus achieved.

UR - http://www.scopus.com/inward/record.url?scp=84857517087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857517087&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84857517087

VL - 66

SP - 167

EP - 170

JO - Japanese Journal of Clinical Urology

JF - Japanese Journal of Clinical Urology

SN - 0385-2393

IS - 2

ER -